Exploration of Medicine

Table 1. Clinical development pipeline of Ibalizumab, including registered study titles, phases, sponsors, and enrolment status as recorded on ClinicalTrials.gov.

NCT number	Study title	Status	Sponsor	Phase	Start	End
NCT02707861	Ibalizumab + optimised background regimen (OBR) in treatment-experienced multidrug-resistant human immunodeficiency virus-1 (MDR HIV-1) patients (TMB-301)	Completed	TaiMed Biologics Inc.	III	2016-03	2018-11
NCT00784147	Dose-response study of Ibalizumab + OBR in HIV-1 patients (TMB-202)	Completed	TaiMed Biologics Inc.	IIb	2008-08	2011-04
NCT00089700	TNX-355 with optimised background therapy in treatment-experienced HIV-1	Unknown	Tanox	II	2004-03	—
NCT01056393	Continued use of Ibalizumab — investigator-sponsored protocol (TMB-311)	Completed	Kaiser Permanente	II	2009-11	2016-12
NCT02028819	Compassionate use of ibalizumab for HIV treatment	No longer available	University of Colorado	—	2012-01	2014-02
NCT02475629	Ibalizumab + OBR in patients with multi-drug resistant HIV	Completed	TaiMed Biologics Inc.	III	2015-08	2016-12
NCT03913195	Safety of Trogarzo™ as undiluted intravenous push or intramuscular injection	Completed	TaiMed Biologics Inc.	III	2019-05	2022-10
NCT01292174	Safety study of ibalizumab subcutaneous injection in healthy volunteers	Completed	TaiMed Biologics Inc.	I	2011-02	2012-09
NCT05388474	Prospective and retrospective observational study of MDR HIV outcomes with and without Ibalizumab	Recruiting	Theratechnologies	—	2022-03	Ongoing
NCT05890963	10E8.4/iMab bispecific antibody and VRC07-523LS in HIV-infected adults	Recruiting	David Ho	I	2023-11	Ongoing

Return to article view

Declarations

Acknowledgments

We ethically used CHAT GPT and Perplexity AI to construct the summative infographic and to proofread for errors and syntax.

The authors would like to acknowledge THE LIND LEAGUE, Nigeria for providing the invaluable resources—human resource and intellectual imbursement—to kick start, culminate and leverage this research project while also enabling our capacities.

Author contributions

PA: Conceptualization, Methodology, Investigation, Formal analysis, Writing—original draft, Writing—review & editing, Visualization, Project administration, Supervision. SB: Methodology, Investigation, Writing—original draft, Writing—review & editing, Validation. EA: Investigation, Writing—original draft, Writing—review & editing. EE: Investigation, Formal analysis, Writing—review & editing, Validation. NM: Investigation, Resources, Writing—review & editing. OA: Investigation, Writing—original draft, Writing—review & editing. NOC: Investigation, Formal analysis, Writing—review & editing. OJN: Investigation, Visualization, Writing—review & editing. BC: Investigation, Writing—review & editing, Validation. VA: Methodology, Validation, Writing—review & editing. AG: Supervision, Validation, Writing—review & editing. JAT: Investigation, Writing—review & editing, Validation. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

World Health Organization. HIV and AIDS [Internet]. WHO; c2026 [cited 2026 Apr 22]. Available from: https://www.who.int/news-room/fact-sheets/detail/hiv-aids

Kumah E, Boakye DS, Boateng R, Agyei E. Advancing the Global Fight Against HIV/Aids: Strategies, Barriers, and the Road to Eradication. Ann Glob Health. 2023;89:83. [DOI] [PubMed] [PMC]

Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011;1:a006841. [DOI] [PubMed] [PMC]

Barré-Sinoussi F, Ross AL, Delfraissy J. Past, present and future: 30 years of HIV research. Nat Rev Microbiol. 2013;11:877–83. [DOI] [PubMed]

Diana B, Tomas C, Romas G, Devi S. HIV: progress and future challenges in treatment, prevention and cure. Nature. 2018.

Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197(Suppl 3):S272–8. [DOI] [PubMed]

Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother. 2009;53:450–7. [DOI] [PubMed] [PMC]

Beccari MV, Mogle BT, Sidman EF, Mastro KA, Asiago-Reddy E, Kufel WD. Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection. Antimicrob Agents Chemother. 2019;63:e00110–19. [DOI] [PubMed] [PMC]

Markham A. Ibalizumab: First Global Approval. Drugs. 2018;78:781–5. [DOI]

10.

European Medicines Agency. Summary of product characteristics [Internet]. [cited 2026 Feb 15] Available from: https://ec.europa.eu/health/documents/community-register/2021/20210421151567/anx_151567_en.pdf

11.

Beran C, Duggan JM, Sahloff EG. A Narrative Review of Novel Agents for Managing Heavily Treatment-Experienced People Living With HIV. J Pharm Technol. 2024;40:194–201. [DOI] [PubMed] [PMC]

12.

Song R, Franco D, Kao CY, Yu F, Huang Y, Ho DD. Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients. J Virol. 2010;84:6935–42. [DOI] [PubMed] [PMC]

13.

Pace CS, Fordyce MW, Franco D, Kao C, Seaman MS, Ho DD. Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope. J Acquir Immune Defic Syndr. 2013;62:1–9. [DOI] [PubMed]

14.

Lin HH, Lee SSJ, Wang NC, Lai Y, Kuo KL, Weinheimer S, et al. Intramuscular ibalizumab: pharmacokinetics, safety, and efficacy vs IV administration. Proceedings of Conference on Retroviruses and Opportunistic Infections. 2017.

15.

Fessel WJ, Anderson B, Follansbee SE, Winters MA, Lewis ST, Weinheimer SP, et al. The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment. Antiviral Res. 2011;92:484–7. [DOI] [PubMed] [PMC]

16.

Chahine EB, Durham SH. Ibalizumab: The First Monoclonal Antibody for the Treatment of HIV-1 Infection. Ann Pharmacother. 2021;55:230–9. [DOI] [PubMed]

17.

Wensel D, Sun Y, Davis J, Li Z, Zhang S, McDonagh T, et al. GSK3732394: a Multi-specific Inhibitor of HIV Entry. J Virol. 2019;93:e00907–19. [DOI] [PubMed] [PMC]

18.

Azzman N, Gill MSA, Hassan SS, Christ F, Debyser Z, Mohamed WAS, et al. Pharmacological advances in anti-retroviral therapy for human immunodeficiency virus-1 infection: A comprehensive review. Rev Med Virol. 2024;34:e2529. [DOI] [PubMed]

19.

Tebas P. Future of bNAbs in HIV Treatment. Curr HIV/AIDS Rep. 2025;22:34. [DOI] [PubMed] [PMC]

20.

Gathe JC, Hardwicke RL, Garcia F, Weinheimer S, Lewis ST, Cash RB. Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study. J Acquir Immune Defic Syndr. 2021;86:482–9. [DOI] [PubMed] [PMC]

21.

Brogan A, Talbird S, Davis AE, La EM, Miao Z, Lewis ST. Long-term health benefit of ibalizumab in the treatment of adults with multidrug-resistant HIV-1 infection. Value Health. 2018;21:S12. [DOI]

22.

Shchelokov D, Demin O Jr. Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study. MAbs. 2023;15:2156317. [DOI] [PubMed] [PMC]

23.

Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1 [Internet]. [cited 2026 Jun 13]. Available from: https://clinicaltrials.gov/study/NCT02707861

24.

Ernst JK, Keefer M, Lalezari J, Goepfert P, Schrader S, Devente J, et al. Subcutaneous ibalizumab in at-risk healthy subjects. Proceedings of ICAAC 2014 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014 Sep 5–9; Washington, DC: NATAP; 2014.

25.

Burkly LC, Olson D, Shapiro R, Winkler G, Rosa JJ, Thomas DW, et al. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Nat Biotechnol. 1992;149:1779–87. [DOI]

26.

Poignard P, Moulard M, Golez E, Vivona V, Franti M, Venturini S, et al. Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies. J Virol. 2003;77:353–65. [DOI]

27.

Victor Garcia J. Humanized mice for HIV and AIDS research. Curr Opin Virol. 2016;19:56–64. [DOI] [PubMed] [PMC]

28.

Zhang C, Zaman LA, Poluektova LY, Gorantla S, Gendelman HE, Dash PK. Humanized Mice for Studies of HIV-1 Persistence and Elimination. Pathogens. 2023;12:879. [DOI] [PubMed] [PMC]

29.

Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States [Internet]. [cited 2026 Apr 24]. Available from: https://clinicalinfo.hiv.gov/en/guidelines/perinatal

30.

Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis. 2004;189:286–91. [DOI] [PubMed]

31.

Towner W, DeJesus E, Schrader S, De Vente J, McGary CS, Zogheib M, et al. Long-Term Efficacy, Safety, and Durability of Ibalizumab-Based Regimens in Subgroup of TMB-202 Participants. Open Forum Infect Dis. 2020;7(Suppl 1):S542–3. [DOI]

32.

Bettiker RL, Koren DE, Jacobson JM. Ibalizumab. Curr Opin HIV AIDS. 2018;13:354–8. [DOI] [PubMed]

33.

Emu B, DeJesus E, Berhe M, Leider J, Creticos C, Weinheimer S, et al. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311). Open Forum Infect Dis. 2019;6(Suppl 2):S303. [DOI]

34.

Blair HA. Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection. Drugs. 2020;80:189–96. [DOI] [PubMed]

35.

Prokesch RC, Schroeder CP, Hardin TC, Van Anglen LJ. Real-World Use of Ibalizumab in Physician Office Infusion Centers (POICs). Open Forum Infect Dis. 2019;6(Suppl 2):S865. [DOI]

36.

FDA Approves TROGARZO (ibalizumab-uiyk) for Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Heavily Treatment-Experienced Adults with Multidrug Resistant HIV-1 Infection Failing Current Antiretroviral Regimen [Internet]. American College of Clinical Pharmacology; [cited 2026 May 16]. Available from: https://accp1.org/Members/ACCP1/5Publications_and_News/TROGARZO-Treatment-HIV-1-Adults-Failing-Current-Antiretroviral-Regimen.aspx

37.

Drugs and Lactation Database (LactMed®) [Internet]. [cited 2026 Apr 23]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK500968/

38.

Ibalizumab Pregnancy and Breastfeeding Warnings [Internet]. Drugs.com; c2000–2026 [cited 2026 Apr 14]. Available from: https://www.drugs.com/pregnancy/ibalizumab.html

39.

Stratigakis A, Paty D, Zou P, Zhao Z, Li Y, Zhang T. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed. 2023;3:199–207. [DOI]

40.

Anderson PO. Monoclonal Antibodies During Breastfeeding. Breastfeed Med. 2021;16:591–3. [DOI] [PubMed]

41.

Feyissa GT, Lockwood C, Woldie M, Munn Z. Reducing HIV-related stigma and discrimination in healthcare settings: A systematic review of quantitative evidence. PLoS One. 2019;14:e0211298. [DOI] [PubMed] [PMC]

42.

Rintamaki L, Kosenko K, Hogan T, Scott AM, Dobmeier C, Tingue E, et al. The Role of Stigma Management in HIV Treatment Adherence. Int J Environ Res Public Health. 2019;16:5003. [DOI] [PubMed] [PMC]

43.

Rintamaki LS, Davis TC, Skripkauskas S, Bennett CL, Wolf MS. Social stigma concerns and HIV medication adherence. AIDS Patient Care STDS. 2006;20:359–68. [DOI] [PubMed]

44.

Aidsmap. Injectable HIV medications must be practical and affordable, conference hears [Internet]. Terrence Higgins Trust; c2026 [cited 2026 Apr 13]. Available from: https://www.aidsmap.com/news/mar-2021/injectable-hiv-medications-must-be-practical-and-affordable-conference-hears

45.

Spreen WR, Margolis DA, Pottage JC Jr. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS. 2013;8:565–71. [DOI] [PubMed] [PMC]

46.

Myburgh H, Reynolds L, Hoddinott G, van Aswegen D, Grobbelaar N, Gunst C, et al. Implementing ‘universal’ access to antiretroviral treatment in South Africa: a scoping review on research priorities. Health Policy Plan. 2021;36:923–38. [DOI] [PubMed] [PMC]

47.

VanderVeen L, Margot N, Naik V, Dvory-Sobol H, Rhee M, Callebaut C. Resistance analysis of long-acting lenacapavir in treatment-naïve people with HIV at 54 weeks. Proceedings of the AIDS 2022 Conference; 2022 Jul 29–Aug 2; NATAP; 2022.

48.

Margot NA, Naik V, VanderVeen L, Anoshchenko O, Singh R, Dvory-Sobol H, et al. Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir. J Infect Dis. 2022;226:1985–91. [DOI] [PubMed]

49.

Sheikh V, Murray JS, Sherwat A. Ibalizumab in Multidrug-Resistant HIV - Accepting Uncertainty. N Engl J Med. 2018;379:605–7. [DOI] [PubMed]